ArticleCurrent microbiology2025
Overexpression of CASP-3, CASP-8, CASP-9 and P53 in HT-29 Cancer Cells after Co-Treatment of New Strain of Lactobacillus Crispatus Extract and Doxorobixin and Complementary Docking Study.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the study was isolation of best probiotic from woman's vagina and evaluate its anticancer properties and the toxicity of the secondary metabolites of the best isolated strain against the HT-29 cancer cells. Vaginal samples were collected from the cervix of healthy women in the north of Iran (Guilan). Molecular identification of the best lactobacillus isolate with probiotic properties was performed. Then, apoptotic and antiproliferative effects of the extract of the new isolate were evaluated compared to doxorubicin. Additionally, a docking study was conducted using USCF Chimera and AutoDock Vina software with 18 ligands and four target proteins, including caspase-3, caspase-8, caspase-9, and P53. Our results showed that the extract of Lactobacillus crispatus strain AE (GenBank: PX247516, IC50 of 1.54 mg/ml) induced apoptosis and inhibited cancer cell growth. In addition, the extract of Lactobacillus crispatus in combination with doxorubicin chemotherapeutic drug had anticancer properties more than the probiotic or doxorubicin alone. Overexpression of CASP-3, CASP-8, CASP-9 and P53 was found in combination therapy with the probiotic or doxorubicin in HT-29 cells by Q-RT-PCR Ligand No. 18 showed strong interactions with the target proteins 1JOX and 1YXQ, with affinities of -7.46 kcal/mol and - 9.622 kcal/mol, respectively. These results confirm a higher stability in docking interactions. Our analysis suggested that a new strain of Lactobacillus crispatus AE (GenBank: PX247516) from vigina as a probiotic can have anticancer effects. This is from the rare reports about this specie of genus Lactobacillus with strong anticancer activity against HT 29 cell lines. The best molecular docking results was detected in the secondary metabolite content encoded as 5,10-dideazatetrahydrofolic acid with an affinity of -9.622 kcal/mol and formed 10 hydrogen bonds with the target protein 1JXQ, resulting in the most stable docking.
Indexed as
Identifiers
41320686What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.